Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral minoxidil can improve hair and eyebrow growth and increase the density of the frontotemporal hairline in patients with FFA, though adverse effects were reported by a third of participants.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

In this study, NH Asian alopecia areata patients reported the highest levels of severe disease, with NH White patients having the most eyebrow involvement and Hispanic patients showing the least severity.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

Pharmacists play a crucial role in improving treatment outcomes and staying updated on various health conditions.

In this cross-sectional study conducted at Farhat Hached Hospital in Tunisia, more than half of the 60 alopecia areata patients surveyed experienced depression, particularly younger individuals and those with severe or specific forms of the condition, underscoring the need for psychological support.

This case report describes a 78-year-old male with adenocarcinoma and Hypertrichosis lanuginosa acquisita, highlighting the need to consider malignancy in patients with unexplained excessive hair growth.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This study reports that cancer patients experiencing chemotherapy-induced alopecia actively engage in Facebook groups for support, instructions, and product recommendations related to scalp cooling, but only 5% consult dermatologists for hair loss concerns, highlighting the platform's influence on patient treatment decisions.

Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.

This study found that the SBN system effectively evaluates and describes the severity and clinical variant of alopecia areata using a standardized scale, aiding in patient management and disease course prediction.

Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

This article discusses ciliary madarosis as a transient condition secondary to IAC, emphasizing the value of physical and trichoscopic evaluations for diagnosis and prognosis; it does not report new clinical results.

In this case report, a 30-year-old woman with sudden eyebrow and eyelash hair loss was treated using Ayurvedic methods including herbal decoctions, leech therapy, and oil massage, resulting in significant hair regrowth by the 45th and 60th days.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

In this case report, a 45-year-old Jordanian woman was diagnosed with Clouston syndrome, an autosomal-dominant disorder characterized by alopecia and nail dystrophy due to a mutation in the GJB6 gene, though she lacked the typical palmoplantar keratoderma.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This case report describes a rare instance of familial congenital atrichia in a 16-year-old girl, possibly involving a genetic component, as both her parents exhibit similar clinical features.

This case report describes a patient who developed Trichodysplasia spinulosa, a folliculocentric viral infection, after heart transplantation, and experienced improvement in her skin condition following modulation of immunosuppressive therapy and application of topical cidofovir.

This article reviews the indications for micropigmentation in dermatological conditions like stable vitiligo and alopecia, but presents no new clinical results.

This case report describes a 7-year-old boy who developed telogen effluvium resulting in unilateral ciliary madarosis nine weeks after COVID-19 infection, with no other causes identified.

This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This protocol outlines a study aiming to develop a universal patient-reported outcome measure for various hair disorders through qualitative interviews, with no new clinical results reported yet.

This article discusses a journal-based CME activity on rare viral skin eruptions in pediatric transplant patients and reports no new clinical results; it aims to improve physicians' knowledge and treatment of this condition.

The document concludes that specialized hair transplant techniques can be effective, with varying success rates depending on the donor area and patient factors.

This study reported that prompt diagnosis and treatment with 5-alpha-reductase inhibitors and topical immunomodulators are key to mitigating the effects of frontal fibrosing alopecia and preventing permanent hair loss.

This piece discusses various considerations in trauma surgery to restore the form and function of affected areas and does not provide new clinical results.